Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
9.37
Dollar change
+0.69
Percentage change
7.95
%
IndexRUT P/E- EPS (ttm)-3.99 Insider Own43.14% Shs Outstand13.01M Perf Week38.20%
Market Cap121.90M Forward P/E- EPS next Y-2.08 Insider Trans1.13% Shs Float7.40M Perf Month5.78%
Income-51.50M PEG- EPS next Q-0.91 Inst Own11.47% Short Float10.61% Perf Quarter5.04%
Sales0.00M P/S- EPS this Y30.33% Inst Trans- Short Ratio1.46 Perf Half Y112.86%
Book/sh-1.87 P/B- EPS next Y37.91% ROA-122.07% Short Interest0.79M Perf Year-53.61%
Cash/sh0.80 P/C11.77 EPS next 5Y- ROE-827.71% 52W Range4.00 - 40.60 Perf YTD18.91%
Dividend Est.- P/FCF- EPS past 5Y52.49% ROI- 52W High-76.92% Beta0.01
Dividend TTM- Quick Ratio0.44 Sales past 5Y12.77% Gross Margin- 52W Low134.02% ATR (14)1.32
Dividend Ex-Date- Current Ratio0.44 EPS Y/Y TTM36.67% Oper. Margin0.00% RSI (14)59.36 Volatility20.35% 16.69%
Employees24 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.14 Target Price39.86
Option/ShortNo / No LT Debt/Eq- EPS Q/Q47.67% Payout- Rel Volume2.84 Prev Close8.68
Sales Surprise- EPS Surprise19.57% Sales Q/Q- EarningsFeb 14 BMO Avg Volume536.26K Price9.37
SMA2019.91% SMA5016.36% SMA200-35.58% Trades Volume1,469,214 Change7.95%
Date Action Analyst Rating Change Price Target Change
Mar-27-24Upgrade BTIG Research Neutral → Buy $50
Feb-15-24Upgrade Chardan Capital Markets Neutral → Buy $3
Jan-25-24Upgrade Guggenheim Neutral → Buy
Dec-27-23Upgrade CapitalOne Equal Weight → Overweight $5
Aug-31-23Downgrade H.C. Wainwright Buy → Neutral $5 → $1
Aug-31-23Downgrade Chardan Capital Markets Buy → Neutral
Aug-30-23Downgrade Guggenheim Buy → Neutral
Aug-30-23Downgrade CapitalOne Overweight → Equal Weight
Aug-30-23Downgrade Cantor Fitzgerald Overweight → Neutral $4.50 → $1
Aug-30-23Downgrade BTIG Research Buy → Neutral
Mar-22-24 07:35AM
Mar-18-24 05:10PM
Mar-12-24 08:05AM
Mar-06-24 03:36PM
Feb-25-24 01:37PM
05:27PM Loading…
Feb-14-24 05:27PM
08:05AM
Jan-31-24 08:05AM
Jan-24-24 08:06AM
Jan-23-24 08:00AM
Jan-02-24 10:18PM
Dec-27-23 02:03PM
09:30AM
Dec-26-23 02:15PM
Dec-22-23 08:05AM
08:05AM Loading…
Dec-19-23 08:05AM
Dec-06-23 08:05AM
Nov-27-23 08:05AM
06:30AM
Nov-15-23 02:04PM
Nov-14-23 08:05AM
Nov-09-23 08:52AM
Nov-02-23 08:05AM
Nov-01-23 08:05AM
Oct-17-23 05:22PM
Oct-11-23 05:49PM
Sep-29-23 08:05AM
Sep-21-23 08:05AM
Sep-05-23 08:05AM
Aug-31-23 10:15AM
06:11AM Loading…
Aug-30-23 06:11AM
06:00AM
Aug-28-23 11:47AM
Aug-14-23 09:55AM
08:05AM
Aug-01-23 08:45AM
Jun-11-23 08:45AM
Jun-06-23 01:59PM
May-15-23 08:05AM
Apr-27-23 08:05AM
Apr-10-23 11:43AM
Mar-13-23 07:00AM
Feb-14-23 08:05AM
Feb-07-23 08:05AM
Jan-19-23 08:05AM
Jan-11-23 01:00PM
Jan-09-23 08:05AM
Jan-02-23 07:31AM
Dec-29-22 09:05AM
Dec-23-22 09:00AM
06:00AM
Dec-22-22 08:05AM
Dec-01-22 08:05AM
Nov-22-22 08:05AM
Nov-01-22 09:55AM
Oct-28-22 08:05AM
Oct-05-22 06:09AM
Sep-27-22 08:05AM
Sep-26-22 08:35AM
Sep-07-22 08:05AM
Aug-30-22 09:39AM
08:05AM
Aug-15-22 08:05AM
Aug-10-22 08:05AM
Aug-04-22 08:05AM
Jul-26-22 07:18AM
Jul-05-22 08:05AM
Jun-14-22 08:05AM
May-31-22 08:05AM
May-27-22 07:25AM
May-18-22 08:05AM
May-13-22 08:05AM
May-10-22 08:35AM
May-09-22 08:35AM
May-04-22 12:02PM
Apr-22-22 08:05AM
Apr-05-22 08:05AM
Apr-04-22 07:45PM
Mar-31-22 08:05AM
Mar-03-22 08:05AM
Feb-24-22 08:05AM
Feb-16-22 10:59AM
Feb-14-22 08:05AM
Feb-10-22 08:05AM
Feb-08-22 08:05AM
Feb-02-22 05:38PM
08:05AM
Jan-25-22 08:05AM
Jan-19-22 08:05AM
Jan-12-22 10:35AM
Jan-04-22 08:35AM
Dec-22-21 08:05AM
Dec-15-21 08:05AM
Dec-09-21 08:05AM
Nov-29-21 04:15PM
Nov-24-21 06:49AM
Nov-23-21 10:30PM
04:30PM
Nov-13-21 11:00AM
Nov-10-21 08:05AM
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Evanson JeffCHIEF COMMERCIAL OFFICERMar 07 '24Buy0.4262,48426,243808,459Mar 11 04:43 PM
Dagnon TerryChief Operations OfficerApr 20 '23Sale1.14520,000590,200653,058Apr 21 09:05 PM